CHI Short Course Announced – Technical Advise on Assay Development, Validation and Sample Analysis

Sept. 19, 2011 - PRLog -- CHI will hold the following pre-conference short course prior to the start of its Immunogenicity Summit 2011.  The course will be held on Tuesday, November 15 from 9:00 a.m. – 12:30 p.m.

Technical Advise on Assay Development, Validation and Sample Analysis

This interactive session will enable attendees to work out an immunogenicity pre-clinical and clinical testing protocol for their particular therapeutic protein. Recent advances will be presented and areas of difficulty will be addressed. Attendees are encouraged to contribute with their own experiences and to bring questions for discussion.

The following topics will be covered:

* Immunogenicity concerns for different types of product
* Assay methodologies
* Critical issues in assay validation
* Challenges to anticipate
* Application step to discuss sample analysis and any relevant issues

Instructors:

Deborah Finco, Ph.D., Immunogenicity Lead, Immunotoxicology COE, Drug Safety R&D, Pfizer, Inc.
Jaya Goyal, Ph.D., Senior Scientist, Clinical Science & Technology, Biogen Idec, Inc.

For more information and to register, please visit http://www.healthtech.com/imn.  CHI will reward advance summit registrations up until October 7.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com